Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications Program and webcast to begin at 8:00 am ET LONDON, March 07,...
-
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
-
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
-
Autolus Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares LONDON – 26 June 2018 – Autolus Therapeutics plc...
-
Autolus Announces Pricing of Initial Public Offering LONDON – 22 June, 2018 – Autolus Therapeutics plc (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T...
-
Autolus Secures US$80 million Series C Funding Proceeds will be used to establish clinical proof of concept for three novel haematological cancer programs London, 26 September 2017 -...